HSD17B11 and metabolic dysfunction-associated steatotic liver disease: Having shown that HSD17β11 expression is negatively associated with hepatic steatosis in humans with MASLD (Fig. 1) and that HSD17β11 deletion induces lipid accumulation in hepatocytes (Fig. 4), we hypothesized that HSD17β11 is required to prevent hepatic steatosis, especially in diet-induced obesity.